Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies – page 7

1 888 clinical trials in Ottignies, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies

Open in trial search

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazucorilant
  • Sponsor:Corcept Therapeutics Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Napazimone
  • Sponsor:Pharming Technologies B.V.

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

B-cell lymphoma

Recruiting

A study comparing AZD0486 after reduced chemotherapy versus standard chemotherapy in older or unfit patients with newly diagnosed large B-cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

A study to assess the safety of anumigilimab in adults with sickle cell disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anumigilimab
  • Sponsor:CSL Behring LLC

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies

What the registry says about research in the country

01 Neurology and Consciousness Disorders

Clinical research in Ottignies includes studies focused on nervous system diseases and the recovery of patients with disorders of consciousness after severe brain injury or coma. These trials are exploring whether targeted therapies can improve wakefulness, responsiveness, and overall neurological recovery.

  • Evaluation of ketamine for post-comatose patients with impaired consciousness
  • Assessment of apomorphine hydrochloride for severe brain injury and consciousness recovery
  • Study of zolpidem responses in patients with disorders of consciousness
  • Research into the mechanisms behind paradoxical neurological responses

Together, these trials aim to improve treatment options and deepen understanding of how the brain may respond to therapy in complex neurological conditions.

02 Respiratory Infections and Critical Care

Another active area of research covers respiratory tract diseases, especially severe community-acquired pneumonia and broader respiratory tract infection care in hospitalized patients. The goal is to identify better ways to support recovery and reduce serious outcomes in people admitted with acute infections.

  • Testing supportive interventions for hospitalized patients with acute respiratory tract infection
  • Evaluating treatment options for severe community-acquired pneumonia
  • Measuring effects on survival and recovery over time

This line of research is particularly relevant for intensive care settings, where timely and effective treatment can strongly influence patient outcomes.

03 Oncology and Breast Cancer

In the field of neoplasms, trials are studying advanced breast cancer with specific genetic features, including ER-positive and HER2-negative disease. Research is centered on whether new treatment combinations can improve disease control in patients with hard-to-treat cancers.

  • Testing a combination approach for selected metastatic breast cancer patients
  • Focusing on tumors with BRCA and HRR alterations
  • Assessing benefits in patients with advanced hormone-receptor-positive disease

These studies are designed to evaluate treatment effectiveness and offer more personalized options for people with genetically defined cancer subtypes.

04 Epilepsy and Rare Neurological Syndromes

Research in nervous system diseases also includes long-term treatment studies for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. The emphasis is on improving seizure control while keeping therapy safe and tolerable over time.

  • Long-term safety evaluation of soticlestat as add-on therapy
  • Support for patients already receiving standard epilepsy care
  • Focus on chronic management of Dravet syndrome and Lennox-Gastaut syndrome

This research is important for families and clinicians seeking better options for rare and severe seizure disorders.

05 Women’s Health and Viral Infections

Within female urogenital diseases and pregnancy-related conditions, clinical trials are examining human papillomavirus infection and strategies to help clear persistent genital HPV. The main purpose is to test whether new approaches can improve infection outcomes and reduce long-term risk.

  • Comparing a candidate intervention with placebo for genital HPV clearance
  • Targeting high-risk oncogenic HPV infections
  • Supporting prevention efforts in women’s health

This area links infection control with cancer prevention, making it a meaningful focus in preventive medicine.

06 Vision Research and Physiological Responses

A smaller but distinctive research stream examines physiological processes in people with acquired partial or total vision impairments and in neurotypical volunteers. These studies aim to better understand unusual responses to treatment and how such responses may inform personalized care.

  • Studying temporary visual improvement in patients with vision impairments
  • Comparing responses in volunteers and patient groups
  • Exploring how unusual drug responses may reveal biological mechanisms

The findings may help clarify why some individuals respond differently to the same treatment and support more tailored clinical decisions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.